{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T12:10:03Z","timestamp":1746274203157,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T00:00:00Z","timestamp":1402963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s40261-014-0206-1","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T13:10:59Z","timestamp":1403183459000},"page":"537-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Calcium Carbonate, Sevelamer Hydrochloride or Pantoprazole on the Pharmacokinetics of Cinacalcet"],"prefix":"10.1007","volume":"34","author":[{"given":"Desmond","family":"Padhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"issue":"Suppl","key":"206_CR1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 1999;73(Suppl):S14\u20139.","journal-title":"Kidney Int."},{"issue":"4 Suppl 3","key":"206_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","volume":"42","author":"G Eknoyan","year":"2003","unstructured":"Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):1\u2013201.","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"206_CR3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1523-1755.2001.0590031187.x","volume":"59","author":"WG Goodman","year":"2001","unstructured":"Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59(3):1187\u2013201.","journal-title":"Kidney Int."},{"issue":"6","key":"206_CR4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0026-895X(24)13280-4","volume":"53","author":"LG Hammerland","year":"1998","unstructured":"Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF. Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol. 1998;53(6):1083\u20138.","journal-title":"Mol Pharmacol."},{"issue":"7","key":"206_CR5","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95(7):4040\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"206_CR6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","volume":"13","author":"WG Goodman","year":"2002","unstructured":"Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002;13(4):1017\u201324.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"206_CR7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","volume":"63","author":"JS Lindberg","year":"2003","unstructured":"Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium\u00a0\u00d7\u00a0phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63(1):248\u201354.","journal-title":"Kidney Int."},{"issue":"3","key":"206_CR8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","volume":"14","author":"LD Quarles","year":"2003","unstructured":"Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14(3):575\u201383.","journal-title":"J Am Soc Nephrol."},{"key":"206_CR9","unstructured":"de Francisco ALM, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P, et al. Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): results of a European\/Australian phase 3 study. J Am Soc Nephrol. 2003;14(Suppl):461A (abstract)."},{"key":"206_CR10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Goodman WG. Cinacalcet HCl for the treatment of secondary hyperparathyroidism in hemodialysis patients. N Engl J Med. 2004;350:1516\u201325.","journal-title":"N Engl J Med."},{"key":"206_CR11","unstructured":"Moe SM, Couburn JW, Quarles LD, et al. Achievement of proposed NKF-K\/DOQI bone metabolism and disease targets: treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism (HPT). J Am Soc Nephrol. 2003;14(Suppl):48A (abstract)."},{"issue":"3","key":"206_CR12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/ndt\/18.3.570","volume":"18","author":"H Strid","year":"2003","unstructured":"Strid H, Simr\u00e9n M, Bj\u00f6rnsson ES. Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrol Dial Transplant. 2003;18(3):570\u20135.","journal-title":"Nephrol Dial Transplant."},{"issue":"Suppl 3","key":"206_CR13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2036.1999.00021.x","volume":"13","author":"TJ Humphries","year":"1999","unstructured":"Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999;13(Suppl 3):18\u201326.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"206_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-199835020-00003","volume":"35","author":"RD Negro","year":"1998","unstructured":"Negro RD. Pharmacokinetic drug interactions with anti-ulcer drugs. Clin Pharmacokinet. 1998;35(2):135\u201350.","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"206_CR15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00003495-199957060-00003","volume":"57","author":"PN Maton","year":"1999","unstructured":"Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57(6):855\u201370.","journal-title":"Drugs."},{"key":"206_CR16","unstructured":"ICH harmonised tripartite guideline: guideline for good clinical practice. 8. Essential documents for the conduct of a clinical trial. J Postgrad Med. 2001;47(4):264\u20137."},{"issue":"18","key":"206_CR17","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/jama.1996.03530420056036","volume":"275","author":"M Feldman","year":"1996","unstructured":"Feldman M. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. JAMA. 1996;275(18):1428\u201331.","journal-title":"JAMA."},{"issue":"10","key":"206_CR18","first-page":"704","volume":"97","author":"MS Lin","year":"1998","unstructured":"Lin MS, Sun P, Yu HY. Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids. J Formos Med Assoc. 1998;97(10):704\u201310.","journal-title":"J Formos Med Assoc."},{"issue":"4","key":"206_CR19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1600-6143.2007.02136.x","volume":"8","author":"AL Serra","year":"2008","unstructured":"Serra AL, Braun SC, Starke A, Savoca R, Hersberger M, Russmann S, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008;8(4):803\u201310.","journal-title":"Am J Transplant."},{"key":"206_CR20","unstructured":"FDA, Guidance for industry\u2014in vivo drug metabolism\/drug interaction studies\u2014stud design, data analysis, and recommendations for dosing and labeling. November 1999, National Press Office: Rockville. http:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/981001gd.pdf . Accessed 5 May 2014."},{"issue":"5","key":"206_CR21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00002018-199819050-00003","volume":"19","author":"HE Bays","year":"1998","unstructured":"Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf. 1998;19(5):355\u201371.","journal-title":"Drug Saf."},{"key":"206_CR22","unstructured":"Sevelamer HCl (Renagel) prescribing information, available at http:\/\/www.renagel.com\/docs\/renagel_pi.pdf . Accessed 12 Jan 2007."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-014-0206-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0206-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:43:04Z","timestamp":1746272584000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-014-0206-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0206-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2014,6,17]]}}}